<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076424</url>
  </required_header>
  <id_info>
    <org_study_id>NDSU-PS</org_study_id>
    <nct_id>NCT03076424</nct_id>
  </id_info>
  <brief_title>The Effect of Nutrient Intake on the Microbiome, Weight, and Glucoregulation (NI-MWG)</brief_title>
  <acronym>NI-MWG</acronym>
  <official_title>Is Weight Change and Glucoregulation Related to Dietary Intake, the Gut Microbiome or the Interaction Between The Two Variables?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Dakota State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neuropsychiatric Research Institute, Fargo, North Dakota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>North Dakota State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate a persons dietary intake and its effect on the&#xD;
      gut microbiome and the association of those two variables on weight and glucoregulation.&#xD;
      Specifically, the investigators will compare the gut microbiota, fasting glucose and insulin,&#xD;
      c-peptide and hemoglobin A1-c in three groups of subjects: obese patients (BMI ≥ 30 kg/m2)&#xD;
      with type 2 diabetes mellitus (T2DM), obese patients without T2DM, and normal weight lean&#xD;
      controls without T2DM. Each patient will also complete a detailed dietary recall (ASA-24) to&#xD;
      investigate the association with diet, microbiome and weight/glucoregulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intestinal Microbiome Composition</measure>
    <time_frame>One sample collected upon study enrollment</time_frame>
    <description>The ratio of firmicutes to bacteroidetes will be the primary focus of the microbiome evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>One sample collected upon study enrollment</time_frame>
    <description>Serum glucose (fasting) will be measured from collected blood sample and compared between the 3 subject groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin</measure>
    <time_frame>One sample collected upon study enrollment</time_frame>
    <description>Plasma insulin (fasting) will be measured from collected blood sample and compared between the 3 subject groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>One sample collected upon study enrollment</time_frame>
    <description>c-peptide will be measured from collected blood sample and compared between the 3 subject groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1-c</measure>
    <time_frame>One sample collected upon study enrollment</time_frame>
    <description>hemoglobin A1-c will be measured from collected blood sample and compared between the 3 subject groups.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">19</enrollment>
  <condition>Obesity</condition>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Obese patients (BMI greater than or equal to 30 kg/m2) with Type 2 Diabetes Mellitus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Obese patients (BMI greater than or equal to 30 kg/m2) without Type 2 Diabetes Mellitus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Normal weight lean controls without Type 2 Diabetes Mellitus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention used</intervention_name>
    <description>Patients will be giving a blood sample after 8 hours of fasting.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma/serum samples and fecal samples will be collected from each patient.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Obese diabetics, obese non-diabetics and controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female&#xD;
&#xD;
          2. Age 18-65 (inclusive, at time of informed consent)&#xD;
&#xD;
          3. BMI ≥ 30 kg/m2 with T2DM&#xD;
&#xD;
          4. BMI ≥ 30 kg/m2 without T2DM&#xD;
&#xD;
          5. Normal weight lean controls without T2DM&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Tobacco use in past three months - will add unnecessary confound to the data.&#xD;
&#xD;
          2. Taking a medication on a routine/recent basis which is known to significantly&#xD;
             influence gastrointestinal transit time or affect the microbiome or other variables&#xD;
             significantly (as determined by study pharmacist/MD)&#xD;
&#xD;
          3. Has taken an oral or injectable antibiotic in the past 3 months&#xD;
&#xD;
          4. Has taken a commercially prepared probiotic and/or prebiotic agent in the 3 months&#xD;
&#xD;
          5. History of significant intestinal disease or disorder (e.g., crohn's disease,&#xD;
             ulcerative colitis)&#xD;
&#xD;
          6. History of gastrointestinal surgery that may impact measures of biological variables,&#xD;
             as determined by the investigator&#xD;
&#xD;
          7. Medical condition expected to impact the biological variables of interest or interfere&#xD;
             with providing a sample, as determined by the investigator.&#xD;
&#xD;
          8. Unable to speak/read English&#xD;
&#xD;
          9. Breastfeeding, pregnant, or planning to become pregnant within the duration of the&#xD;
             study as assessed through self-report on medical history&#xD;
&#xD;
         10. Unwilling to use a medically acceptable form of contraception during study&#xD;
             involvement. Medically acceptable forms of contraception include oral contraception,&#xD;
             physical barrier methods and/or abstinence.&#xD;
&#xD;
         11. Any known infectious disease such as Viral Hepatitis or HIV (as determined by study&#xD;
             pharmacist/MD)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Neuropsychiatric Research Institute (NRI)</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Dakota State University</investigator_affiliation>
    <investigator_full_name>Kristine Steffen</investigator_full_name>
    <investigator_title>Associate Professor, Pharm. D., Ph.D.</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

